Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $320,400.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $26.70, for a total transaction of $320,400.00. Following the sale, the insider now directly owns 1,093,035 shares of the company’s stock, valued at $29,184,034.50. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $23.22 on Friday. The firm has a market cap of $1.09 billion, a P/E ratio of -12.03 and a beta of 1.10. The firm has a fifty day moving average of $22.82 and a two-hundred day moving average of $19.56. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.26 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on ELVN shares. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird began coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price objective for the company. Finally, Mizuho initiated coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Enliven Therapeutics by 17.8% in the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock worth $187,000 after buying an additional 2,041 shares during the last quarter. AJOVista LLC bought a new position in shares of Enliven Therapeutics in the 4th quarter worth about $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $167,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.